One year ago, Indiana-based Endocyte Inc. bought the rights to a prostate cancer treatment for $12 million, plus future considerations. On Thursday, Novartis AG agreed to pay almost 200 times that amount to acquire Endocyte and the experimental therapy.
The Indiana Seed Fund III is an early-stage fund focused on developing startups in life sciences, health IT and agricultural biosciences.
The physicians’ group claims the Connersville health system misled it on patient volumes and has refused to adjust a subsidy to make up the difference.
The Justice Department’s approval clears the way for a merger that will create a health care giant with a hand in insurance, prescription-drug benefits and drugstores across the United States.
The U.S. Food and Drug Administration will make it easier for pharmaceutical companies to bring more complex—and more profitable—generic drugs to market, throwing the struggling industry a crucial lifeline.
Visits to emergency rooms in Indiana for drug overdoses are falling, and doctors are writing fewer prescriptions for opioid painkillers, Jim McClelland said Friday.
Eli Lilly and Co. received clearance Thursday from U.S. regulators for a new migraine drug that will be the third in a promising class of therapies for patients who suffer from the recurrent, painful headaches.
The Indianapolis health system said it has not yet decided how to develop the site, but wants to keep its options open. It dropped plans four months ago to rezone the land after neighbors objected.
Indiana University Health isn’t shy about telling the world how it stacks up in U.S. News & World Report’s “Best Hospital” annual rankings.
The Indianapolis-based health system said it is in discussions with officials from Frankfort and Clinton County to build a new hospital to replace a 25-bed facility that is more than 60 years old.
The Eli Lilly and Co.-owned animal medicine maker’s shares rose to $36 each at closing Thursday, up from their $24 offering price.
Greenfield-based Elanco Animal Health Inc. raised more than expected in its initial public offering, pricing its shares above the marketed price range.
The competition for the multi-billion dollar migraine market is set to heat up with the FDA expected to decide on Lilly’s migraine therapy next month.
The sale to True Nature Holding Inc. is expected to close by October. Neither party would say whether the Indianapolis operations would remain here.
An estimated 85,000 low-income Hoosiers who receive Medicaid benefits will soon need to find a job, volunteer, get job training, or go to school—or risk losing health care for a few months.
The Indianapolis medical-software firm recently raised $10 million in venture funding and is launching two major products in one month.
The hospital system said the facility would help meet the soaring demand for hip and knee replacements while also serving patients with the “most complex” orthopedic conditions.
The lawsuit by a former medical director alleges St. Vincent engaged in a practice of “pushing out employees over the age of 40 and hiring substantially younger employees.”
The “Roche Academy” will provide mentors, internships and special curriculum to biology and chemistry undergrads, along with financial incentives and a job offer after graduation.
The Indianapolis-based drugmaker has appealed its annual tax bill for its two massive campuses south of downtown every year since 2012.
